Literature DB >> 17620345

Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.

Yan Zheng1, Dongxiao Sun, Arun K Sharma, Gang Chen, Shantu Amin, Philip Lazarus.   

Abstract

1-[4-(2-Dimethylaminoethoxy)-phenyl]-1,2-diphenylbut-1-(Z)-ene (tamoxifen, TAM) is a nonsteroidal antiestrogen that has been commonly used for the prevention and treatment of estrogen receptor-positive breast cancer. TAM is extensively metabolized into several primary active metabolites including 4-hydroxy-TAM (4-OH-TAM) and endoxifen. Glucuronidation is the major phase II metabolic pathway important in their excretion. Whereas high antiestrogenic activity has been reported for both 4-OH-TAM and endoxifen, studies examining the effect of glucuronide conjugation of these metabolites have not previously been performed. In the present study, the antiestrogenic activities of glucuronidated TAM metabolites were determined by examining their effect on the induction of the estrogen-responsive progesterone receptor (PGR) gene. 17beta-Estradiol (E(2))-mediated PGR gene expression in MCF-7 cells was determined by real-time reverse transcriptase-polymerase chain reaction for each TAM metabolite isomer. E(2) (1 x 10(-10) M) induction of PGR mRNA was 6-fold after a 12-h incubation; only unconjugated TAM metabolites inhibited this effect. A virtually identical dose-dependent inhibition of E(2)-induced PGR gene expression was found for both the trans- and cis-isomers of 4-OH-TAM and endoxifen, with maximal inhibition attained at 1 x 10(-6) M of TAM metabolite. The glucuronide conjugates of all 4-OH-TAM and endoxifen isomers exhibited no effect on E(2)-mediated induction of PGR expression at all concentrations of TAM metabolite examined in this study. These data indicate that isomers of both 4-OH-TAM and endoxifen exhibit roughly equipotent antiestrogenic effects on E(2)-induced gene expression and that glucuronide conjugates of the same metabolites effectively negate this activity. This result may have important implications in terms of both whole-body and target tissue-specific glucuronidation pathways and individual responses to TAM therapy and cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620345     DOI: 10.1124/dmd.107.016279

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  18 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Functional polymorphisms in UDP-glucuronosyl transferases and recurrence in tamoxifen-treated breast cancer survivors.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Håvard Søiland; Jennifer Gjerde; Jens Peter Garne; Carol L Rosenberg; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-07-12       Impact factor: 4.254

Review 3.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

4.  Computer-aided design and synthesis of tetra-aryl-substituted alkenes and their bioevaluation as a selective modulator of estrogen-related receptor γ.

Authors:  Minseob Koh; Seung Bum Park
Journal:  Mol Divers       Date:  2010-02-05       Impact factor: 2.943

5.  Bayesian Pathway Analysis for Complex Interactions.

Authors:  James W Baurley; Anders Kjærsgaard; Michael E Zwick; Deirdre P Cronin-Fenton; Lindsay J Collin; Per Damkier; Stephen Hamilton-Dutoit; Timothy L Lash; Thomas P Ahern
Journal:  Am J Epidemiol       Date:  2020-12-01       Impact factor: 4.897

6.  Disposition of hop prenylflavonoids in human breast tissue.

Authors:  Selin Bolca; Jinghu Li; Dejan Nikolic; Nathalie Roche; Phillip Blondeel; Sam Possemiers; Denis De Keukeleire; Marc Bracke; Arne Heyerick; Richard B van Breemen; Herman Depypere
Journal:  Mol Nutr Food Res       Date:  2010-07       Impact factor: 5.914

7.  Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer.

Authors:  Changde Zhang; Qiu Zhong; Qiang Zhang; Shilong Zheng; Lucio Miele; Guangdi Wang
Journal:  Breast Cancer Res Treat       Date:  2015-06-14       Impact factor: 4.872

8.  Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue.

Authors:  Thomas P Ahern; Mariann Christensen; Deirdre P Cronin-Fenton; Kathryn L Lunetta; Carol L Rosenberg; Henrik Toft Sørensen; Timothy L Lash; Stephen Hamilton-Dutoit
Journal:  Clin Epidemiol       Date:  2010-10-22       Impact factor: 4.790

9.  Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.

Authors:  Dongxiao Sun; Nathan R Jones; Andrea Manni; Philip Lazarus
Journal:  Cancer Prev Res (Phila)       Date:  2013-05-16

10.  Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.

Authors:  Philip Lazarus; Dongxiao Sun
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.